Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 419

1.

Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy.

Driessen CML, Leijendeckers J, Snik A, van der Graaf WTA, de Boer JP, Gelderblom H, Kaanders JHAM, Takes R, van Herpen CML.

Head Neck. 2018 Dec 7. doi: 10.1002/hed.25434. [Epub ahead of print]

PMID:
30536479
2.

Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry.

Boonstra PA, Steeghs N, Farag S, van Coevorden F, Gelderblom H, Grunhagen DJ, Desar IME, van der Graaf WTA, Bonenkamp JJ, Reyners AKL, van Etten B.

Eur J Surg Oncol. 2018 Oct 16. pii: S0748-7983(18)31432-X. doi: 10.1016/j.ejso.2018.09.013. [Epub ahead of print]

PMID:
30416078
3.

Age-related sarcoma patient experience: results from a national survey in England.

Younger E, Husson O, Bennister L, Whelan J, Wilson R, Roast A, Jones RL, van der Graaf WT.

BMC Cancer. 2018 Oct 17;18(1):991. doi: 10.1186/s12885-018-4866-8.

4.

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv79-iv95. doi: 10.1093/annonc/mdy310. No abstract available.

PMID:
30285218
5.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv268-iv269. doi: 10.1093/annonc/mdy321. No abstract available.

PMID:
30285214
6.

Caregivers of patients receiving long-term treatment with a tyrosine kinase inhibitor (TKI) for gastrointestinal stromal tumour (GIST): a cross-sectional assessment of their distress and burden.

Langenberg SMCH, Reyners AKL, Wymenga ANM, Sieling GCM, Veldhoven CMM, van Herpen CML, Prins JB, van der Graaf WTA.

Acta Oncol. 2018 Oct 3:1-9. doi: 10.1080/0284186X.2018.1518592. [Epub ahead of print]

PMID:
30280630
7.

Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management.

Owen C, Constantinidou A, Miah AB, Thway K, Fisher C, Benson C, Zaidi S, Messiou C, VAN DER Graaf WTA, Jones RL.

Anticancer Res. 2018 Sep;38(9):5275-5282. doi: 10.21873/anticanres.12853. Review.

PMID:
30194178
8.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv267. doi: 10.1093/annonc/mdy320. No abstract available.

PMID:
30188977
9.

Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma.

Chew W, Benson C, Thway K, Hayes A, Miah A, Zaidi S, Lee ATJ, Messiou C, Fisher C, van der Graaf WT, Jones RL.

Med Oncol. 2018 Sep 5;35(11):138. doi: 10.1007/s12032-018-1192-6.

10.

Desmoid fibromatosis through the patients' eyes: time to change the focus and organisation of care?

Husson O, Younger E, Dunlop A, Dean L, Strauss DC, Benson C, Hayes AJ, Miah A, van Houdt W, Zaidi S, Smith M, Williams J, Jones RL, van der Graaf WTA.

Support Care Cancer. 2018 Aug 28. doi: 10.1007/s00520-018-4386-8. [Epub ahead of print]

PMID:
30155568
11.

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Aug 21;8(1):12771. doi: 10.1038/s41598-018-30922-8.

12.

Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands.

van Broekhoven DLM, Verschoor AJ, van Dalen T, Grünhagen DJ, den Bakker MA, Gelderblom H, Bovee JVMG, Haas RLM, Bonenkamp HJ, van Coevorden F, Ten Oever D, van der Graaf WTA, Flucke UE, Pras E, Reyners AKL, Westermann AM, Oldenburger F, Verhoef C, Steeghs N.

Sarcoma. 2018 Jun 21;2018:5982575. doi: 10.1155/2018/5982575. eCollection 2018.

13.

Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.

Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang JE, Chenard-Poiriér M, Collins D, Lim J, Ameratunga M, Khan K, Kaye SB, Banerji U, Lopez J, George AJ, de Bono JS, van der Graaf WT.

Eur J Cancer. 2018 Sep;101:55-61. doi: 10.1016/j.ejca.2018.06.003. Epub 2018 Jul 17.

14.

Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study.

Timbergen MJM, van de Poll-Franse LV, Grünhagen DJ, van der Graaf WT, Sleijfer S, Verhoef C, Husson O.

Qual Life Res. 2018 Dec;27(12):3097-3111. doi: 10.1007/s11136-018-1931-3. Epub 2018 Jul 16. Review.

PMID:
30014458
Free PMC Article
15.

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z. Erratum in: Sci Rep. 2018 Aug 21;8(1):12771.

16.

Targeted Therapy-based Combination Treatment in Rhabdomyosarcoma.

van Erp AEM, Versleijen-Jonkers YMH, van der Graaf WTA, Fleuren EDG.

Mol Cancer Ther. 2018 Jul;17(7):1365-1380. doi: 10.1158/1535-7163.MCT-17-1131. Review.

PMID:
29967215
17.

Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.

Boon E, Valstar MH, van der Graaf WTA, Bloemena E, Willems SM, Meeuwis CA, Slootweg PJ, Smit LA, Merkx MAW, Takes RP, Kaanders JHAM, Groenen PJTA, Flucke UE, van Herpen CML.

Oral Oncol. 2018 Jul;82:29-33. doi: 10.1016/j.oraloncology.2018.04.022. Epub 2018 May 11.

18.

Psychosocial challenges and health-related quality of life of adolescents and young adults with hematologic malignancies.

Husson O, Huijgens PC, van der Graaf WTA.

Blood. 2018 Jul 26;132(4):385-392. doi: 10.1182/blood-2017-11-778555. Epub 2018 Jun 12. Review.

PMID:
29895664
19.

Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response.

Libertini M, Mitra I, van der Graaf WTA, Miah AB, Judson I, Jones RL, Thomas K, Moskovic E, Szucs Z, Benson C, Messiou C.

Clin Sarcoma Res. 2018 May 14;8:13. doi: 10.1186/s13569-018-0100-3. eCollection 2018.

20.

Age-related differences in health-related quality of life among thyroid cancer survivors compared with a normative sample: Results from the PROFILES Registry.

Mols F, Schoormans D, Smit JWA, Netea-Maier RT, Links TP, van der Graaf WTA, Husson O.

Head Neck. 2018 Oct;40(10):2235-2245. doi: 10.1002/hed.25325. Epub 2018 May 13.

PMID:
29756245
21.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2018 May 5. doi: 10.1093/annonc/mdx823. [Epub ahead of print] No abstract available.

PMID:
29741569
22.

Health-Related Quality of Life in Patients With Sarcoma: Enhancing Personalized Medicine.

Younger E, Wilson R, van der Graaf WTA, Husson O.

J Clin Oncol. 2018 Jun 1;36(16):1642-1643. doi: 10.1200/JCO.2018.77.9819. Epub 2018 Apr 18. No abstract available.

PMID:
29668370
23.

Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era.

van der Graaf WTA, Tielen R, Bonenkamp JJ, Lemmens V, Verhoeven RHA, de Wilt JHW.

Br J Surg. 2018 Jul;105(8):1020-1027. doi: 10.1002/bjs.10809. Epub 2018 Apr 17.

24.

Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.

Younger E, Litière S, Le Cesne A, Mir O, Gelderblom H, Italiano A, Marreaud S, Jones RL, Gronchi A, van der Graaf WTA.

Oncologist. 2018 Oct;23(10):1250-1259. doi: 10.1634/theoncologist.2017-0598. Epub 2018 Apr 12.

PMID:
29650688
25.

The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.

McVeigh TP, Sundar R, Diamantis N, Kaye SB, Banerji U, Lopez JS, de Bono J, van der Graaf WTA, George AJ.

Eur J Cancer. 2018 May;95:20-29. doi: 10.1016/j.ejca.2018.02.028. Epub 2018 Mar 31.

26.

Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study.

Verschoor AJ, Litière S, Marréaud S, Judson I, Toulmonde M, Wardelmann E, van der Graaf WT, Le Cesne A, Gronchi A, Gelderblom H.

Eur J Cancer. 2018 May;94:187-198. doi: 10.1016/j.ejca.2018.02.015. Epub 2018 Mar 22.

PMID:
29574364
27.

A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors.

Boonstra PA, Ter Elst A, Tibbesma M, Bosman LJ, Mathijssen R, Atrafi F, van Coevorden F, Steeghs N, Farag S, Gelderblom H, van der Graaf WTA, Desar IME, Maier J, Overbosch J, Suurmeijer AJH, Gietema J, Schuuring E, Reyners AKL.

Oncotarget. 2018 Feb 14;9(17):13870-13883. doi: 10.18632/oncotarget.24493. eCollection 2018 Mar 2.

28.

European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.

Touati N, Schöffski P, Litière S, Judson I, Sleijfer S, van der Graaf WT, Italiano A, Isambert N, Gil T, Blay JY, Stark D, Brodowicz T, Marréaud S, Gronchi A.

Clin Oncol (R Coll Radiol). 2018 Jul;30(7):448-454. doi: 10.1016/j.clon.2018.02.065. Epub 2018 Mar 15.

PMID:
29550245
29.

Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database.

Sleijfer S, Rizzo E, Litière S, Mathijssen RHJ, Judson IR, Gelderblom H, Van Der Graaf WTA, Gronchi A.

Acta Oncol. 2018 Aug;57(8):1117-1126. doi: 10.1080/0284186X.2018.1449248. Epub 2018 Mar 9.

PMID:
29521151
30.

Systemic Treatment for Adults with Synovial Sarcoma.

Desar IME, Fleuren EDG, van der Graaf WTA.

Curr Treat Options Oncol. 2018 Mar 7;19(2):13. doi: 10.1007/s11864-018-0525-1. Review.

31.

A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.

Boon E, Bel M, van Boxtel W, van der Graaf WTA, van Es RJJ, Eerenstein SEJ, Baatenburg de Jong RJ, van den Brekel MWM, van der Velden LA, Witjes MJH, Hoeben A, Willems SM, Bloemena E, Smit LA, Oosting SF; PALGA Group, Jonker MA, Flucke UE, van Herpen CML.

Int J Cancer. 2018 Aug 15;143(4):758-766. doi: 10.1002/ijc.31353. Epub 2018 Mar 23.

32.

Systemic treatment in adult uterine sarcomas.

Desar IME, Ottevanger PB, Benson C, van der Graaf WTA.

Crit Rev Oncol Hematol. 2018 Feb;122:10-20. doi: 10.1016/j.critrevonc.2017.12.009. Epub 2017 Dec 14. Review.

33.

Young adults: a unique group in cancer epidemiological research.

Husson O, Lidington E, Younger E, van der Graaf WT.

Lancet Oncol. 2018 Feb;19(2):e72. doi: 10.1016/S1470-2045(18)30029-9. No abstract available.

PMID:
29413473
34.

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).

Lindner LH, Litière S, Sleijfer S, Benson C, Italiano A, Kasper B, Messiou C, Gelderblom H, Wardelmann E, Le Cesne A, Blay JY, Marreaud S, Hindi N, Desar IME, Gronchi A, van der Graaf WTA.

Int J Cancer. 2018 Jun 15;142(12):2610-2620. doi: 10.1002/ijc.31286. Epub 2018 Feb 14.

35.

Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.

Boon E, van Boxtel W, Buter J, Baatenburg de Jong RJ, van Es RJJ, Bel M, Fiets E, Oosting SF, Slingerland M, Hoeben A, Tesselaar MET, Jonker MA, Flucke UE; Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) Group, van der Graaf WTA, van Herpen CML.

Head Neck. 2018 Mar;40(3):605-613. doi: 10.1002/hed.25035. Epub 2017 Dec 22.

36.

Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial.

Driessen CML, Groenewoud JMM, de Boer JP, Gelderblom H, van der Graaf WTA, Prins JB, Kaanders JHAM, van Herpen CML.

Support Care Cancer. 2018 Apr;26(4):1233-1242. doi: 10.1007/s00520-017-3946-7. Epub 2017 Dec 11.

37.

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthoney A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S, Stacchiotti S.

Ann Oncol. 2018 Mar 1;29(3):758-765. doi: 10.1093/annonc/mdx774.

PMID:
29216400
38.

Prevalence and correlates of high fear of cancer recurrence in late adolescents and young adults consulting a specialist adolescent and young adult (AYA) cancer service.

Thewes B, Kaal SEJ, Custers JAE, Manten-Horst E, Jansen R, Servaes P, van der Graaf WTA, Prins JB, Husson O.

Support Care Cancer. 2018 May;26(5):1479-1487. doi: 10.1007/s00520-017-3975-2. Epub 2017 Nov 22.

39.

Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.

Farag S, van Coevorden F, Sneekes E, Grunhagen DJ, Reyners AKL, Boonstra PA, van der Graaf WT, Gelderblom HJ, Steeghs N.

Eur J Cancer. 2017 Nov;86:318-325. doi: 10.1016/j.ejca.2017.09.017. Epub 2017 Oct 23.

PMID:
29073582
40.

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.

van Erp AEM, Hillebrandt-Roeffen MHS, van Houdt L, Fleuren EDG, van der Graaf WTA, Versleijen-Jonkers YMH.

Target Oncol. 2017 Dec;12(6):815-826. doi: 10.1007/s11523-017-0528-z.

41.

Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent.

van Erp AEM, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, van Houdt L, Gorris MAJ, van Dam LS, Mentzel T, Weidema ME, Savci-Heijink CD, Desar IME, Merks HHM, van Noesel MM, Shipley J, van der Graaf WTA, Flucke UE, Meyer-Wentrup FAG.

Oncotarget. 2017 Jul 7;8(41):71371-71384. doi: 10.18632/oncotarget.19071. eCollection 2017 Sep 19.

42.

ATR Is a Therapeutic Target in Synovial Sarcoma.

Jones SE, Fleuren EDG, Frankum J, Konde A, Williamson CT, Krastev DB, Pemberton HN, Campbell J, Gulati A, Elliott R, Menon M, Selfe JL, Brough R, Pettitt SJ, Niedzwiedz W, van der Graaf WTA, Shipley J, Ashworth A, Lord CJ.

Cancer Res. 2017 Dec 15;77(24):7014-7026. doi: 10.1158/0008-5472.CAN-17-2056. Epub 2017 Oct 16.

43.

Early Evaluation of Response Using 18F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib.

Farag S, Geus-Oei LF, van der Graaf WT, van Coevorden F, Grunhagen D, Reyners AKL, Boonstra PA, Desar I, Gelderblom H, Steeghs N.

J Nucl Med. 2018 Feb;59(2):194-196. doi: 10.2967/jnumed.117.196642. Epub 2017 Sep 28.

PMID:
28970330
44.

An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).

Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, Hohenberger P, Penel N, Messiou C, van der Graaf WT, Gronchi A; Desmoid Working Group .

Ann Oncol. 2017 Oct 1;28(10):2399-2408. doi: 10.1093/annonc/mdx323. Review.

45.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2017 Dec 1;28(12):3000-3008. doi: 10.1093/annonc/mdx527.

46.

Post-Traumatic Growth and Resilience in Adolescent and Young Adult Cancer Patients: An Overview.

Greup SR, Kaal SEJ, Jansen R, Manten-Horst E, Thong MSY, van der Graaf WTA, Prins JB, Husson O.

J Adolesc Young Adult Oncol. 2018 Feb;7(1):1-14. doi: 10.1089/jayao.2017.0040. Epub 2017 Sep 8.

PMID:
28885875
47.

Decision aids for second-line palliative chemotherapy: a randomised phase II multicentre trial.

Oostendorp LJM, Ottevanger PB, Donders ART, van de Wouw AJ, Schoenaker IJH, Smilde TJ, van der Graaf WTA, Stalmeier PFM.

BMC Med Inform Decis Mak. 2017 Aug 31;17(1):130. doi: 10.1186/s12911-017-0529-y.

48.

The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma.

Constantinidou A, van der Graaf WTA.

Eur J Cancer. 2017 Oct;84:257-261. doi: 10.1016/j.ejca.2017.07.043. Epub 2017 Aug 23.

49.

Adherence to Guidelines for Adult (Non-GIST) Soft Tissue Sarcoma in the Netherlands: A Plea for Dedicated Sarcoma Centers.

Hoekstra HJ, Haas RLM, Verhoef C, Suurmeijer AJH, van Rijswijk CSP, Bongers BGH, van der Graaf WT, Ho VKY.

Ann Surg Oncol. 2017 Oct;24(11):3279-3288. doi: 10.1245/s10434-017-6003-3. Epub 2017 Jul 26.

50.

Empowerment in adolescents and young adults with cancer: Relationship with health-related quality of life.

Kaal SEJ, Husson O, van Duivenboden S, Jansen R, Manten-Horst E, Servaes P, Prins JB, van den Berg SW, van der Graaf WTA.

Cancer. 2017 Oct 15;123(20):4039-4047. doi: 10.1002/cncr.30827. Epub 2017 Jul 11.

Supplemental Content

Loading ...
Support Center